Bivalirudin: a new approach to anticoagulation.
Bivalirudin is one of the first of a new class of anticoagulants known as direct thrombin inhibitors. These drugs are able to overcome many of the shortcomings of traditional heparin anticoagulation by virtue of this unique mechanism of action. Bivalirudin is a semisynthetic derivative of hirudin, a modified component of leech saliva. Hirudin has been plagued by bleeding complications, likely due to its high affinity for thrombin. Bivalirudin has lower thrombin affinity than hirudin and therefore is believed to be a much safer compound. Bivalirudin has been shown to be a very effective anticoagulant in laboratory models, though its clinical efficacy remains to be fully proven. Bivalirudin has been studied in the setting of coronary angioplasty, unstable angina, and acute myocardial infarction and has shown some promise in many of these settings, particularly in preventing complications of percutaneous coronary interventions. Bivalirudin has consistently shown less major bleeding compared with standard heparin, although limitations in study methodologies somewhat hinder an accurate interpretation of this finding. Larger-scale studies are indicated and are currently being performed, the results of which will more definitively define the role of bivalirudin for the treatment of cardiovascular disease.
Nawarskas
J J
JJ
College of Pharmacy, University of New Mexico, Albuquerque 87131-5691, USA. nawarska@unm.edu
Anderson
J R
JR
D000789:Angina, Unstable / Q000150:complications / Q000188:drug therapy; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use*; D000991:Antithrombins / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D010446:Peptide Fragments / Q000494:pharmacology* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin